GlassScriptPhysician profile
Catherina Min
NPI 1124469275
$4,290.72
in general payments reported to CMS, 2019-2025
15 companies · $770 in 2025
The $770 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,019 · 2023: $450 · 2024: $2,052 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Travel and Lodging: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.62 |
| Travel and Lodging | $1,077.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,721.25 | 2022-2024 | Acuvue |
| Alcon Vision LLC | $500.78 | 2022-2025 | Total30, Precision 1, Precision 7 |
| Tarsus Pharmaceuticals, INC. | $468.58 | 2024-2025 | Xdemvy |
| Abbvie INC. | $358.52 | 2022-2025 | |
| Glaukos Corporation | $305.17 | 2022-2025 | |
| Oyster Point Pharma, INC. | $246.55 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $194.35 | 2022-2025 | Cequa |
| Biotissue Holdings INC. | $138.84 | 2023-2025 | |
| Notal Vision, INC. | $107.06 | 2022 | |
| Dompe US, INC. | $86.77 | 2022-2025 | Oxervate |
| Coopervision INC. | $56.43 | 2023-2024 | Myday Contact Lens |
| Harrow Eye, LLC | $34.98 | 2025 | Vevye |
| Thea Pharma INC. | $31.07 | 2023 | |
| Bausch & Lomb Americas INC. | $27.78 | 2022-2023 | Miebo |
| Visioneering Technologies, INC. | $12.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherina Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.